肿瘤与老年医学交叉领域的实践变革进展
本文总结了近期三项高影响力试验,这些试验产生了改变实践的启示并促成了指南更新,聚焦于接受治疗的老年癌症患者。关键发现是:以老年评估为指导的干预措施提高了化疗按计划剂量完成率、减少了治疗中的3级血液学和非血液学毒性,并影响晚期癌症患者的治疗决策,在不影响生存的情况下通过降低治疗强度减少毒性。
要点
- 老年评估指导的干预可提高老年癌症患者化疗按计划剂量完成率并减少剂量调整。
- 老年评估指导的干预可减少各分期癌症化疗患者的3级血液学和非血液学毒性。
- 在晚期癌症支持治疗中,老年评估影响决策,降低治疗强度减少毒性且不损害生存。
核心结论
- 以老年评估为指导的干预在老年癌症患者中改善了化疗完成率、减少了毒性,并优化了晚期患者的治疗决策而不影响生存。
研究设计与样本
- 本文总结了近期三项高影响力前瞻性试验,这些试验产生了改变实践的启示并促成了指南更新。
主要发现
- 老年评估指导的干预促进了老年癌症患者以计划剂量完成化疗的比例更高,且剂量调整更少。
- 老年评估指导的干预减少了接受化疗的各分期癌症患者在治疗期间的3级血液学和非血液学毒性。
- 在晚期癌症接受支持治疗的患者中,老年评估指导的干预影响了治疗决策,通过降低治疗强度减少毒性且不损害生存。
临床怎么用
- 对接受治疗的老年癌症患者应考虑采用老年评估指导的干预,以提高化疗完成率并减少毒性。
- 在晚期癌症支持治疗中,可依据老年评估结果调整治疗强度,以降低毒性而不影响生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer and aging are inextricably linked, and older adults are a significant proportion of those diagnosed, treated, and living with and beyond a cancer diagnosis. Several large prospective studies have enhanced our understanding of how to improve the assessment, treatment, and outcomes of older adults with cancer starting therapy. This article summarizes three recent high-impact trials that produced practice-changing implications for the management of older adults with cancer that led to guideline updates. The key findings from these trials highlight that geriatric assessment-guided interventions in older adults with cancer: (1) facilitated higher rates of chemotherapy completion at planned doses with less modification among patients, (2) reduced grade 3 hematologic and non-hematologic toxicity during treatment delivery among patients of all stages of cancer receiving chemotherapy, and (3) influenced treatment decisions among advanced cancer patients receiving supportive care leading to reduced toxicity through reduced intensity of therapy without compromise of survival.
引用
- Phillips T, Ji J, Katheria V, et al. Clin-STAR Corner: Practice Changing Advances at the Interface of Oncology and Geriatrics. J Am Geriatr Soc. 2024. PMID: 39739310. doi:10.1111/jgs.19361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。